Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
04
05
2022
accepted:
16
03
2023
revised:
12
03
2023
medline:
7
6
2023
pubmed:
13
4
2023
entrez:
12
4
2023
Statut:
ppublish
Résumé
The prognostic significance of tumour budding (TB) and minimal cell nest size (MCNS) was shown in human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC). However, the optimisation of cutpoints, the prognostic impact in HPV-positive HNSCC, and the comparison with other histopathological grading systems are insufficiently investigated. TB and MCNS were analysed digitally in 1 and 10 high-power fields (HPF) of 331 HPV-positive and HPV-negative cases from TCGA. Optimising the cutpoints a new cellular dissociation grading (CDG) system was defined and compared to the WHO grading and the Brandwein-Gensler (BG) risk model. The two-tiered CDG system based solely on TB yielded optimal prognostic stratification with shortened overall survival for CDG-high cases. Optimal cut-offs were two buds (1 HPF) and six buds (10 HPF), respectively. Analysing MCNS did not add prognostic significance to quantifying TB. CDG was a significant prognostic marker in HPV-negative and HPV-positive tumours and prognostically superior to the WHO and BG systems. High CDG was associated with clinically occult lymph-node metastases. The most comprehensive study of TB in HNSCC so far confirmed its prognostic impact in HPV-negative tumours and for the first time in HPV-positive tumours. Further studies are warranted to evaluate its applicability for therapy guidance in HNSCC.
Sections du résumé
BACKGROUND
The prognostic significance of tumour budding (TB) and minimal cell nest size (MCNS) was shown in human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC). However, the optimisation of cutpoints, the prognostic impact in HPV-positive HNSCC, and the comparison with other histopathological grading systems are insufficiently investigated.
METHODS
TB and MCNS were analysed digitally in 1 and 10 high-power fields (HPF) of 331 HPV-positive and HPV-negative cases from TCGA. Optimising the cutpoints a new cellular dissociation grading (CDG) system was defined and compared to the WHO grading and the Brandwein-Gensler (BG) risk model.
RESULTS
The two-tiered CDG system based solely on TB yielded optimal prognostic stratification with shortened overall survival for CDG-high cases. Optimal cut-offs were two buds (1 HPF) and six buds (10 HPF), respectively. Analysing MCNS did not add prognostic significance to quantifying TB. CDG was a significant prognostic marker in HPV-negative and HPV-positive tumours and prognostically superior to the WHO and BG systems. High CDG was associated with clinically occult lymph-node metastases.
CONCLUSIONS
The most comprehensive study of TB in HNSCC so far confirmed its prognostic impact in HPV-negative tumours and for the first time in HPV-positive tumours. Further studies are warranted to evaluate its applicability for therapy guidance in HNSCC.
Identifiants
pubmed: 37045906
doi: 10.1038/s41416-023-02240-y
pii: 10.1038/s41416-023-02240-y
pmc: PMC10241901
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2295-2306Informations de copyright
© 2023. The Author(s).
Références
Ann Transl Med. 2019 Jul;7(Suppl 3):S75
pubmed: 31576284
Nat Rev Clin Oncol. 2021 Feb;18(2):101-115
pubmed: 32901132
Head Neck Pathol. 2013 Sep;7(3):211-23
pubmed: 23250819
J Oral Maxillofac Pathol. 2020 Sep-Dec;24(3):587
pubmed: 33967517
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
PLoS One. 2020 Sep 25;15(9):e0239783
pubmed: 32976535
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jun;123(6):688-696
pubmed: 28411003
Ann Oncol. 2017 Oct 1;28(10):2386-2398
pubmed: 28633362
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers Head Neck. 2020 Sep 09;5:11
pubmed: 32944296
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Head Neck. 2019 Feb;41(2):542-550
pubmed: 30549142
Am J Surg Pathol. 2019 May;43(5):618-627
pubmed: 30807302
J Pathol Clin Res. 2018 Apr;4(2):93-102
pubmed: 29665323
Am J Surg Pathol. 2019 Feb;43(2):229-234
pubmed: 30334831
Head Neck. 2019 Oct;41(10):3712-3718
pubmed: 31328847
Int J Oral Maxillofac Surg. 2014 Jul;43(7):795-801
pubmed: 24583139
Head Neck Pathol. 2021 Dec;15(4):1099-1108
pubmed: 33797696
Transl Oncol. 2022 Jul;21:101426
pubmed: 35460943
Oral Dis. 2015 Sep;21(6):755-61
pubmed: 25825335
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Histopathology. 2021 Mar;78(4):476-484
pubmed: 33001500
Int J Oral Maxillofac Surg. 2015 Feb;44(2):143-50
pubmed: 25457829
Cancer Immunol Immunother. 2019 Sep;68(9):1443-1454
pubmed: 31444607
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Am J Surg Pathol. 2019 Mar;43(3):303-313
pubmed: 30475254
J Oral Pathol Med. 2015 Apr;44(4):266-72
pubmed: 25169851
J Oral Pathol Med. 2021 Feb;50(2):183-190
pubmed: 33151566
Am J Surg Pathol. 2019 May;43(5):703-709
pubmed: 30829728
J Clin Med. 2016 Apr 29;5(5):
pubmed: 27136592
Cancer Treat Rev. 2020 Mar;84:101977
pubmed: 32018128
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
Hum Pathol. 2017 Jul;65:62-70
pubmed: 28438617
J Oral Pathol Med. 2012 Jan;41(1):34-9
pubmed: 21902722
Eur Respir J. 2016 Mar;47(3):938-46
pubmed: 26541540
Cancers (Basel). 2020 Jul 03;12(7):
pubmed: 32635357
Sci Rep. 2020 Apr 14;10(1):6395
pubmed: 32286381
Ear Nose Throat J. 2019 Aug;98(7):E112-E119
pubmed: 31072197
Nat Rev Clin Oncol. 2022 May;19(5):306-327
pubmed: 35105976
Virchows Arch. 2021 Sep;479(3):597-606
pubmed: 33661329
Head Neck. 2014 Jun;36(6):811-8
pubmed: 23696499
J Surg Oncol. 2019 Mar;119(3):370-378
pubmed: 30548537
PLoS One. 2018 Aug 30;13(8):e0203403
pubmed: 30161236
Histopathology. 2017 Jun;70(7):1125-1137
pubmed: 28122134
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32719094
Br J Cancer. 2018 Feb 20;118(4):577-586
pubmed: 29190636
PLoS One. 2018 Apr 19;13(4):e0195451
pubmed: 29672550
Oral Dis. 2017 Jan;23(1):120-125
pubmed: 27667675
Oral Oncol. 2010 Sep;46(9):636-43
pubmed: 20637679
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011
Cancer Treat Rev. 2015 Feb;41(2):151-9
pubmed: 25549950
BMC Cancer. 2020 Aug 27;20(1):813
pubmed: 32854649
Am J Surg Pathol. 2005 Feb;29(2):167-78
pubmed: 15644773
Clin Transl Radiat Oncol. 2017 Nov 04;8:4-11
pubmed: 29594236
Histopathology. 2017 May;70(6):869-879
pubmed: 27926795
Cancers (Basel). 2022 Jul 22;14(15):
pubmed: 35892830
Head Neck. 2019 Sep;41(9):2991-3001
pubmed: 31012518
Oral Dis. 2022 Mar;28(2):275-283
pubmed: 33031610
Front Oncol. 2021 Feb 05;10:637513
pubmed: 33634033
Acta Otorhinolaryngol Ital. 2017 Dec;37(6):458-466
pubmed: 28663597